Thus, future studies will examine the inhibition of tumor growth by co-treatment with perifosine and trametinib or PD0325901 in mouse xenograft models of DLD-1, HT-29, our establishment MEK inhibitor resistance cells and patient-derived colorectal cancer cells. Here, MAP2K7 is linked to neoplasm.